Kriya Therapeutics

1.1 Identity and platform

Kriya’s own website consistently frames the company around durable, one-time medicines for chronic diseases and around an integrated development model rather than a single-asset story. That matters because later chapters can treat Kriya as a platform-shaped private biopharma, not just a narrow ophthalmology bet: the medicines page says the clinical-stage pipeline already includes five investigational medicines, while third-party profiles independently cluster the visible disease focus in ophthalmology, metabolic disease, and neurology. The combined read is a company trying to industrialize gene therapy for larger patient populations, with manufacturing and delivery economics positioned as part of the product thesis.[CO001, CO002, CO003, CO004]

1.2 Leadership, governance, and footprint

The public leadership picture in the assigned pool is directionally clear but not fully complete. Secondary profiles trace Kriya’s founding bench to Shankar Ramaswamy, Fraser Wright, and Roger Jeffs, while current executive references identify Ramaswamy as the operating center of gravity alongside a smaller disclosed team spanning finance, medical, and nonclinical development. Governance visibility is thinner: the strongest specific board datapoint is NCBiotech’s note that Patient Square’s Jim Momtazee joined the board with the 2021 Series B. Location evidence is also mixed in a useful way: several sources place Kriya in both Research Triangle Park/Durham and Palo Alto/Bay Area, which supports a bi-coastal operating footprint but not a clean single-headquarters convention.[CO005, CO006, CO007, CO008, CO009]

1.3 Financing and milestones

Funding scale is clearly part of the Kriya narrative, but the public record is still uneven. NCBiotech directly reports a $100 million Series B in 2021, and PackGene later reports a $313.3 million 2025 financing tied to an SEC filing whose investors were not named. SetterVC’s tracker fills in additional rounds and a much larger aggregate capital stack, but its own caveat explicitly says the funding, valuation, and employee fields may be incomplete, stale, erroneous, or revised, so those values are better treated as directional context than verified cover metrics. Operationally, the most concrete recent proof points are the KRIYA-825 ophthalmology program reaching Phase 1/2 and the FDA PreCheck pilot selection linked to Kriya’s new commercial facility in RTP.[CO009, CO010, CO011, CO012, CO013, CO014]

1.4 Risk frame and open diligence items

The overview should stay tempered. PatSnap’s R&D synopsis still characterizes the gene-therapy environment as one with complex regulatory requirements, high manufacturing costs, and inherent scientific uncertainties, which is especially relevant for a company leaning hard into scaled AAV manufacturing before public human efficacy data are broad. At the same time, the assigned evidence does not robustly verify several reader-facing basics a diligence report would ideally lock down early: exact total capital raised, current valuation, current headcount, a definitive headquarters convention, current cash runway, and a complete board roster. Those omissions do not invalidate the platform story, but they do constrain how confidently later chapters can underwrite scale, governance depth, and valuation discipline.[CO005, CO012, CO015]

1.5 Exhibits

2.1 Boundary and therapeutic beachheads

The available sources define Kriya's market boundary around durable, one-time AAV medicines for common or highly prevalent chronic diseases, not the earlier rare-disease-only template that has historically dominated commercial gene therapy. Kriya's own medicines page says the company was built to treat chronic diseases affecting millions of patients, and both Foresite Capital and PatSnap frame the company around broader chronic or widespread disease categories rather than niche monogenic disorders. That boundary matters because Kriya's disclosed program mix is spread across ophthalmology, metabolic disease, and neurology. VentureRadar's program list and Kriya's medicines page together show a portfolio that includes geographic atrophy, thyroid eye disease, type 1 diabetes, MASH, and trigeminal neuralgia, with additional undisclosed programs behind those visible assets. In market terms, Kriya is not trying to win one single orphan indication; it is attempting to prove a repeatable product and manufacturing model across several specialist-managed chronic disease categories.[CM001, CM002, CM003, CM004, CM005]

2.2 Sizing signals exist, but the public TAM remains under-specified

The strongest public market signal is breadth and investor appetite, not a rigorously disclosed revenue pool. Kriya and its backers repeatedly use qualitative language such as "common diseases," "millions of patients," and a "very large and heretofore untapped opportunity." Pharmaceutical Technology also reports that the September 2025 Series D was oversubscribed at $320 million, while The BioTech Strategist treats the financing as one of the larger private biotech rounds of 2025. Those are useful capital-market indicators that sophisticated investors believe a large commercial prize may exist. What the assigned evidence still does not provide is the hard market math that would turn that thesis into a defensible TAM, SAM, or SOM. None of the retained sources isolate the addressable spend for Kriya's target disease categories, disclose adoption-rate assumptions, or give a market CAGR that can be tied back to Kriya's specific delivery model. The figure below therefore narrows the opportunity qualitatively from broad chronic disease burden to Kriya's disclosed beachheads instead of assigning unsupported dollar layers.[CM006, CM007, CM008, CM015]

2.3 Adoption depends on commercialization readiness, not science alone

The adoption thesis rests on whether Kriya can make chronic-disease gene therapy manufacturable and operationally repeatable. NCBiotech quotes the company describing the field as constrained by manufacturing technology, vector design capability, and cost, while Kriya's own materials emphasize an integrated product and manufacturing engine built to make durable medicines more scalable. Pharmaceutical Technology ties the 2025 round directly to advancing trials and strengthening the company's manufacturing engine, and PackGene's 2026 FDA PreCheck coverage links commercialization readiness to the new Research Triangle Park facility. Public evidence also shows where the commercial wedge is most concrete. KRIYA-825 is already framed as a one-time suprachoroidal therapy for geographic atrophy intended to reduce the burden of frequent intravitreal injections required by current therapies, which gives Kriya a clearer substitute narrative than it has yet disclosed in metabolic disease or neurology. Even so, the medicines remain investigational and the public source set still does not identify named buyers, payers, or budget owners for each segment, so market timing remains more management thesis than verified procurement evidence.[CM009, CM010, CM011, CM012, CM013, CM014, CM015]

3.1 Competitive landscape spans status quo care, broad AAV platforms, and adjacent gene-editing peers

The retained pool does not support a tight list of direct like-for-like commercial rivals for Kriya's current lead program, but it does show the main classes of alternatives a buyer or investor would compare. At the indication level, KRIYA-825 is being developed for geographic atrophy, where Kriya's own framing explicitly compares a one-time suprachoroidal AAV therapy with currently available therapies that require repeated physician-administered intravitreal injections. At the company level, SetterVC's profile places Kriya beside broad platform peers such as 4D Molecular Therapeutics, uniQure, Editas Medicine, Sana Biotechnology, Beam Therapeutics, and Capsida Therapeutics, which means Kriya is being benchmarked less as a single-asset ophthalmology bet and more as a scaled gene-therapy platform competing for capital, talent, and future indication expansion.[CP001, CP003, CP005, CP008, CP011]

3.2 Public differentiation rests on treatment burden, validated biology, and platform breadth

Kriya's public argument against the status quo is straightforward: KRIYA-825 targets validated complement pathways and aims to replace chronic re-treatment with a one-time administration. The official ARVO release says the program targets complement C3 and C5, calls out existing FDA-approved medicines in geographic atrophy, and frames KRIYA-825 as an attempt to avoid the repeated injection burden of today's regimen. That matters because it gives Kriya a buyer-facing value proposition rooted in administration burden rather than only in molecule novelty. At the same time, the same sources emphasize that KRIYA-825 remains investigational and that clinical safety and efficacy have not yet been established, so the company still competes on prospective product design rather than on proven switching behavior.[CP002, CP003, CP014, CP016]

3.3 Manufacturing control is the most credible lock-in signal in the retained pool

The most defensible moat signal in the assigned evidence is upstream rather than commercial. Kriya's medicines page says the company was built to make durable medicines for common diseases at scale, while PackGene says the platform combines AAV vector engineering, process development, analytical testing, and GMP capabilities and that the FDA selected Kriya for the PreCheck Pilot Program tied to its planned commercial facility. Those details do not prove customer lock-in yet, but they do suggest that Kriya is trying to control supply, process know-how, and regulatory readiness internally instead of outsourcing the hardest parts of scale-up. In practice, that makes internal build and supply-chain execution more relevant competitive battlegrounds than list-price undercutting at this stage.[CP004, CP006, CP007, CP010]

3.4 Moat claims are still provisional because peer and pricing evidence remain thin

The main adverse read is not that a better competitor has already outpriced or outdistributed Kriya in the retained pool; it is that the public benchmark is still too shallow to prove Kriya's advantage. SetterVC explicitly warns that its competitor list may be incomplete, stale, or erroneous, and the assigned sources do not disclose public pricing for KRIYA-825 or for the named peer set. That means the chapter can support a narrower conclusion: Kriya has a plausible differentiation story around one-time dosing, common-disease focus, and integrated manufacturing, but commoditization and displacement risk remain high until direct competitor product data, payer terms, and human efficacy signals make the comparison more concrete.[CP009, CP012, CP013]

3.5 Exhibits

4.1 Current revenue model and monetization visibility

The public evidence still describes Kriya as a clinical-stage platform company rather than a company with disclosed commercial revenue. Kriya's medicines page says the pipeline includes five investigational medicines and explicitly says its durable medicines have not been approved as safe or effective by any regulatory health authority, which materially limits what can be underwritten today on revenue quality or realized gross margin. The accessible market-data pages also do not publish usable pricing, contract, or revenue disclosures; instead, they mainly advertise gated access to private-company financial data. That leaves the public monetization case anchored on future approvals, partnerships, or other commercialization events rather than on current disclosed revenue streams.[CI001, CI002, CI014, CI015]

4.2 Cost structure, manufacturing buildout, and operating leverage

Public sources consistently describe a manufacturing-first operating model that can eventually support scale, but it also implies heavy fixed-cost absorption before product revenue is visible. NCBiotech said Kriya's 2021 Series B proceeds were being used to develop core technology platforms and expand the pipeline, and the same report described a 51,000-square-foot Research Triangle Park manufacturing facility. In July 2026, PackGene reported that FDA selected Kriya for the PreCheck pilot based on plans for a new commercial facility in Research Triangle Park expected to support pipeline products already in clinical trials. PackGene also described a proprietary data system with more than 80 million datapoints, which supports the argument that process development and manufacturing know-how could become an eventual margin lever, but only after Kriya clears clinical and regulatory milestones that are still in front of it.[CI009, CI010, CI011, CI012]

4.3 Capital base, valuation markers, and adequacy

Kriya looks well financed relative to most private biotech companies, but the exact starting point is still fuzzy. The official May 2025 ARVO release said Kriya had raised over $600 million, FundedIQ lists $914 million across five rounds with a $313 million latest round in August 2025, SetterVC lists $920 million across five rounds and an $8 billion valuation mark as of August 15, 2025 while warning that its funding and valuation marks may be incomplete or erroneous, and biotech.gallery says the company is backed by over $1.2 billion. Those ranges are directionally consistent with strong financing access but not precise enough to underwrite current cash, dilution, or step-up discipline. The strongest public positive is that Kriya was still investing in commercialization-readiness infrastructure in 2026, but the missing cash balance, burn, and runway disclosure means capital adequacy remains an open underwriting issue.[CI003, CI005, CI006, CI007, CI008, CI011, CI016]

4.4 Financial verdict and diligence blockers

The financial verdict is that Kriya currently reads as a capital-intensive, milestone-driven private gene-therapy platform with credible access to capital but limited public evidence on revenue quality, pricing power, or near-term self-funding potential. The adverse lens is important: one biotech analysis framed the sector as still constrained by manufacturing, safety, and reimbursement hurdles and estimated that a nine-program platform like Kriya could burn $150-200 million annually, which is not a verified company disclosure but is a useful stress-case reminder that integrated gene-therapy infrastructure can consume cash quickly. Until management provides reconciled funding history, post-round cash, burn, runway, launch economics, and payer or partner assumptions, this chapter supports tracking execution rather than underwriting revenue durability.[CI013, CI014, CI015, CI016]

4.5 Exhibits

5.1 Pipeline breadth is real, but public maturity detail is uneven

Kriya positions the product in workflow terms as a one-time durable medicine: deliver DNA once, turn target cells into an ongoing source of therapeutic protein, and replace chronic administration with a single intervention where biology and delivery cooperate. The official medicines page says the company has five investigational medicines in a clinical-stage pipeline and explicitly frames them as designed for chronic diseases affecting millions rather than rare orphan indications. Third-party profiles and listings align on the same three therapeutic corridors—ophthalmology, metabolic disease, and neurology—and add named assets for geographic atrophy, thyroid eye disease, type 1 diabetes, steatotic liver disease, and trigeminal neuralgia. The strongest public maturity proof in the assigned pool is KRIYA-825 in geographic atrophy. MedPath reports that KRIYA-825 had already entered a Phase 1/2 study in 2025 and describes a concrete product design: an AAV therapy expressing a CR2-CR1 fusion protein intended to inhibit complement C3 and C5 after a one-time suprachoroidal delivery. For the rest of the portfolio, public evidence is more thesis-level than execution-level: Kriya and profile sites describe delivery concepts and intended benefits, but they do not provide the same level of stage-by-stage disclosure, deployment detail, or human-readout support. That means the breadth is credible, but maturity is not equally evidenced across all five lead programs.[CE001, CE002, CE006, CE007, CE009, CE010, CE011, CE012, CE014]

5.2 The technical differentiation is vertical integration plus manufacturing readiness

Public technical evidence is much stronger on Kriya's operating model than on application-layer customer deployment. MTEC describes an integrated product engine spanning vector engineering, preclinical and clinical development, analytical sciences, and GMP manufacturing, while the official medicines page says Kriya is trying to collapse the cost and scale barriers that kept durable medicines out of common diseases. PackGene extends that picture with more specific operating detail: Kriya combines AAV vector engineering, process development, analytical testing, and GMP capabilities, and layers on automation, digital technologies, and data-driven optimization to improve quality, scalability, and efficiency. The manufacturing stack is not only rhetorical. PackGene says Kriya was selected for the FDA's PreCheck Pilot Program for a new commercial facility in Research Triangle Park, and SetterVC also flags the selection as a regulatory/manufacturing-readiness signal ahead of commercialization. PackGene further says Kriya's HOPSON structured data system contains more than 80 million internal datapoints, which supports the idea that Kriya's moat is process learning and scale-up discipline as much as asset novelty. That operating model is the clearest product-technology differentiation visible in the assigned pool, and it is also the part of the story with the most concrete readiness markers.[CE001, CE003, CE004, CE005, CE013, CE014, CE015]

5.3 Quality and regulatory signals exist, but public proof is still thin on clinical durability and support

Kriya does have public quality-control signals: the medicines page stresses that the portfolio remains investigational, MedPath repeats that KRIYA-825 is not approved and that clinical safety and efficacy remain unestablished, and PackGene/SetterVC point to manufacturing-readiness engagement with FDA. Those are better signals than generic biotech marketing, but they do not yet amount to comprehensive public proof on reliability, pharmacovigilance workflow, reimbursement support, deployment services, or commercial-scale post-dose monitoring. The biggest product-technical underwriting gap is therefore not whether Kriya has an ambitious architecture; it clearly does. The gap is whether that architecture produces repeatable human efficacy, safe durability, and supportable commercialization across multiple prevalent indications. The assigned pool also lacks a public developer/practitioner signal equivalent—no open repositories, public SDK/docs surface, status page, security center, or independent practitioner forum evidence appeared here—so diligence still needs direct management evidence on operational controls, quality systems, and program-by-program readiness before the platform can be underwritten as more than a well-specified product engine.[CE007, CE008, CE013, CE014]

6.1 Customer base today is still a target-population map, not a disclosed account list

Kriya's current public "customer" surface is best understood as a set of intended patient populations and clinician workflows rather than a live book of commercial accounts. The official medicines page says the company is building "durable medicines at scale to treat common diseases" and describes five clinical-stage investigational medicines across large chronic-disease categories, which frames the eventual user base as ophthalmology, neurology, and metabolic-disease patients treated by specialists rather than current enterprise buyers or hospital systems. Independent summaries repeat that same picture: a broad chronic-disease thesis, significant manufacturing ambition, and multiple therapeutic areas, but no cited payer contracts, named health-system deployments, or disclosed customer counts. That makes segmentation possible at the use-case level, while leaving buyer-versus-user-versus-payer economics largely unproven in the current evidence set.[CU001, CU002, CU003, CU004, CU012, CU014]

6.2 Adoption proof is clinical progression and readiness signals, not production deployment

The clearest adoption evidence in this source pack is movement from platform narrative into clinical and regulatory milestones. Kriya's own materials say five investigational medicines are in the clinical-stage pipeline, while independent summaries and trial-focused articles point to a Phase 1/2 geographic atrophy program and a first-in-human type 1 diabetes study planned for 2026. Those are meaningful proof points that the company has advanced beyond pure research, but they are still patient and investigator engagement inside development programs, not commercial product usage. Likewise, FDA PreCheck participation is a real commercialization-readiness signal because it supports facility design and review preparedness, yet it does not answer whether providers, payers, or procurement channels are ready to buy one-time gene therapies at scale.[CU001, CU005, CU006, CU007, CU009, CU014]

6.3 Named proof remains program-level, and durability evidence is mostly absent

Kriya can point to specific programs and disease populations, but not to named commercial customers or externally verified recurring use. The best public proof points are program-specific: KRIYA-825 in geographic atrophy, the planned PROGRESS study in type 1 diabetes, and the broader company assertion that five investigational medicines are advancing toward commercialization. Even these examples are limited. The geographic atrophy evidence centers on preclinical data and trial initiation; the diabetes evidence centers on a first-in-human study setup; and the corporate materials do not disclose trial-site rosters, reference accounts, human outcomes tied to customer economics, or payer reimbursement evidence. As a result, the chapter can document where proof exists, but the retention and renewal layer that a true customer-quality chapter would normally require is still missing.[CU005, CU006, CU008, CU011, CU013, CU014]

6.4 Expansion depends on data, reimbursement, and concentration visibility that are not yet public

The commercial upside in Kriya's story comes from addressing large chronic diseases with one-time gene therapies, but the current public evidence leaves major adoption frictions unresolved. Independent commentary on the 2025 financing explicitly situates the company inside a gene-therapy market dealing with safety concerns, reimbursement hurdles, and the need for clinical proof before broad uptake can occur. That means land-and- expand logic is still hypothetical: investors can underwrite the platform and Kriya can prepare manufacturing capacity, yet there is no disclosed contract base showing renewals, expansion within a provider system, multi-program cross-sell, or channel resilience. Until Kriya publishes customer names, site density, payer discussions, or post-launch cohort behavior, concentration risk and go-to-market durability remain diligence gaps rather than answered strengths.[CU007, CU010, CU011, CU012, CU013, CU014]

6.5 Exhibits

7.1 Clinical approval risk remains the primary thesis breaker

The core risk is still whether Kriya can convert a broad AAV pipeline into human safety and efficacy evidence that is strong enough for approval in common chronic diseases. Kriya's own medicines page says its durable medicines are investigational and have not been approved as safe or effective by any regulatory health authority, and the same posture is echoed on its news page. The company's May 2025 ARVO release says KRIYA-825 entered a clinical trial earlier that year, but it also states that the product has not been approved and that its clinical safety and efficacy have not yet been established. A separate April 2026 PackGene write-up says the first-in-human PROGRESS study for KRIYA-839 is still structured to evaluate safety and efficacy over 52 weeks, confirming that even the newer diabetes platform remains in an early proof-building stage. For investors, the practical implication is that valuation and platform breadth do not yet offset the absence of public human readouts showing durable efficacy, tolerability, and manufacturability in common-disease settings.[CR001, CR002, CR003, CR004, CR005]

7.2 Manufacturing scale-up and delivery complexity are still unresolved

Kriya's second major risk is operational: the company is trying to move AAV manufacturing, delivery, and quality systems from promising platform rhetoric into repeatable commercial readiness. PackGene's July 2026 summary says the FDA selected Kriya for the PreCheck Pilot Program based on plans for a new commercial facility in Research Triangle Park, and describes the program as early engagement during facility design, construction, and operational readiness rather than proof that the site is already inspection ready. That matches older NCBiotech coverage in which Kriya itself said the field was constrained by manufacturing technology, vector design capabilities, and cost. Program design adds further execution risk: the April 2026 KRIYA-839 article says treatment is expected to involve multiple intramuscular injections plus short-term immune modulation, while KRIYA-825 depends on specialized ocular delivery. These are manageable risks, but they require flawless clinical operations, CMC discipline, and device or procedure consistency to avoid schedule slips.[CR005, CR006, CR007, CR008, CR009, CR016]

7.3 Capital access is strong, but disclosure opacity and partner dependencies remain

Kriya has clearly been able to keep attracting capital, but the public evidence base does not reconcile cleanly and that itself is a risk signal. SetterVC lists total funding at $920 million across five rounds and a latest valuation mark of $8 billion dated August 15, 2025, while also warning that its company data and valuation marks may be incomplete, stale, erroneous, or revised. By contrast, Labiotech says Kriya's September 2025 Series D brought its total funds above $1.2 billion, and separately argues that the company has disclosed little about how its August 2025 financing would be spent. The same Labiotech piece says early KT-A112, KT-A522, and KT-A832 programs no longer appear in the active pipeline and that most of Kriya's nine candidates remain preclinical, raising the possibility that capital has outrun public proof. Dependency risk is also tangible because KRIYA-825's ocular delivery path relies on Everads-linked technology rather than a wholly self-contained product stack.[CR010, CR011, CR012, CR013, CR014, CR015, CR016]

7.4 What would reduce the risk rating, and what would break the thesis

The main mitigants are real but incomplete. FDA PreCheck participation should improve manufacturing dialogue, a multi-program portfolio reduces single-asset dependency, and Kriya has clearly demonstrated access to large financing rounds. None of those mitigants eliminates the need for public human efficacy, safety, and manufacturing evidence. The clearest positive de-risking event would be convincing early clinical data from KRIYA-825 or KRIYA-839 paired with evidence that the RTP manufacturing build is tracking to commercial readiness without material FDA or validation setbacks. The clearest thesis-break triggers are weaker-than-expected Phase 1/2 safety or efficacy signals, visible delays in facility readiness, or a continued inability to reconcile total capital raised, valuation, and runway from current public sources. Until those gaps close, the residual risk profile remains high enough that diligence should focus on data-room proof rather than narrative confidence.[CR004, CR007, CR008, CR013, CR014, CR015]

7.5 Exhibits

8.1 Recommendation posture

The cleanest read from the available evidence is track rather than buy or avoid. Kriya still has ingredients that can create value: the company is funding a broad chronic-disease gene-therapy platform, still appears able to attract large private rounds, and has added a current commercialization-readiness datapoint via FDA PreCheck participation. At the same time, the price evidence is too noisy to underwrite aggressively. Forge shows a September 2025 Series D with an estimated $1.67 billion post-money valuation, while SetterVC shows an August 2025 latest valuation mark of $8 billion and separately warns that its funding and valuation marks may be incomplete, stale, erroneous, or revised. With cash, burn, runway, and broader preference-stack details still undisclosed in public sources, the prudent posture is to watch for better proof or a cheaper entry rather than pay for a premium story on incomplete data.[CV001, CV002, CV003, CV004, CV005, CV008, CV013, CV014, CV015]

8.2 What still supports upside

Kriya remains more than a single-asset biotech bet. Official and investor-facing materials frame the company around durable medicines for common chronic diseases, with five clinical-stage investigational medicines already in the pipeline and a broader follow-on wave intended to compound prior data, manufacturing, and product learnings. Foresite's portfolio description reinforces that the strategy is aimed at highly prevalent serious diseases rather than narrower orphan segments, which is the core reason the company can plausibly earn platform-style optionality if the clinical proof accumulates. The July 2026 FDA PreCheck selection matters because it ties Kriya's Research Triangle Park facility directly to commercial-readiness processes rather than to an abstract manufacturing story. The latest financing also signals that sophisticated capital has not abandoned the platform despite a tough sector tape.[CV005, CV006, CV007, CV008, CV011]

8.3 Why public evidence does not yet support paying up

The central valuation problem is not that there is no signal; it is that the signal set is inconsistent and partially gated. Forge presents specific Series D terms, including price per share and a 1.0x liquidation preference clue, but also states that its post-money valuation is an estimate based on company-submitted certificates of incorporation and that its private-company data are not audited. SetterVC offers a much higher latest valuation mark and a total-raised figure, but it also attaches a direct warning that those marks may be incomplete, stale, erroneous, or revised. EquityZen confirms some secondary-market access and shareholder-liquidity infrastructure, yet reserves cap-table, valuation, and financial detail for logged-in users. On top of that transparency gap, adverse sector coverage still emphasizes safety scrutiny, multi-year-low sentiment, and heavy capital consumption across gene therapy, which limits how much premium one should ascribe before human efficacy and balance-sheet disclosure sharpen the picture.[CV001, CV002, CV003, CV004, CV009, CV010, CV012, CV013, CV015]

8.4 Final diligence asks and thesis-breakers

The remaining diligence agenda is straightforward. First, reconcile the 2025 round history and cap-table stack using primary documents, because public round labels, sizing, and valuation marks do not line up tightly enough for underwriting. Second, get a current cash, burn, and runway view; even a strong platform can be a weak investment if it must refinance before decisive clinical inflection points. Third, get human efficacy, durability, and safety evidence from lead programs, because the long-term upside case ultimately depends on clinical proof rather than on the existence of a manufacturing platform alone. A thesis break would be any combination of disappointing early human data, evidence of a financing overhang or down-round setup, or a sector-safety shock that narrows capital access before Kriya can convert platform claims into commercial proof.[CV002, CV003, CV008, CV010, CV012, CV013, CV014, CV015]

8.5 Exhibits